Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. ANNOUNCES ISSUANCE OF U.S. PATENT

Helix BioPharma Corp. has been issued U.S. patent No. 11931422.

U.S. patent No. 11931422, entitled "Antibody-Urease Conjugates for Therapeutic Purposes," relates to Helix's first-in-class antibody-drug conjugate (ADC) platform, L-DOS47, and the optimization of conjugation ratios for a proprietary antibody that precisely binds to tumour cells expressing high levels of CEACAM6, conjugated to urease, an enzyme capable of alkalizing the acidic tumour microenvironment (TME).

CEACAM6 is a tumour antigen highly expressed on hard-to-treat, prevalent cancers where currently available treatments are not achieving meaningful enough clinical benefits for patients (including non-small cell lung cancer, pancreatic and colorectal cancers). Binding to CEACAM6, Helix's L-DOS47 converts urea into ammonia and alkalizes the TME, promoting tumour regression, restoring function to local immune cells (such as T-cells) and opening the possibility to significantly enhance the treatment outcomes of available established therapies, including chemotherapy, checkpoint inhibitors (immunotherapies) and targeted small molecules.

Jacek Antas, chief executive officer of Helix, stated: "We are very pleased to receive the issuance of this patent in the U.S., an important oncology market with a significant need for novel treatment modalities and better clinical outcomes. The timing is also advantageous, considering our ongoing discussions about expanding our pipeline with synergistic oncology products."

About Helix BioPharma Corp.

Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.

We seek Safe Harbor.